Survival Outcomes in NSCLC Patients with Brain Metastases Under Advanced Treatments

Overview

This study analyzed survival outcomes in 360 metastatic NSCLC patients, comparing those with brain metastases (BM) to those without, in the era of advanced systemic and local therapies. Findings indicate that patients with BM, despite younger age and higher adenocarcinoma prevalence, have survival outcomes approaching those without BM, reflecting improvements in treatment strategies.

Background

Brain metastases are a frequent and serious complication in cancer patients, notably in non-small cell lung cancer (NSCLC), where 16–20% develop BM. Historically, BM conferred poor prognosis and patients with BM were often excluded from clinical trials. Advances in targeted therapies, immunotherapy, and stereotactic radiosurgery have improved intracranial disease control and survival. Genetic mutations such as EGFR and ALK are associated with higher BM incidence and have prognostic significance.

Data Highlights

Key Findings

• Of 360 metastatic NSCLC patients, 37.2% had brain metastases at diagnosis.
• Patients with BM were significantly younger (median 61.5 vs. 69 years) and more often female.
• BM was more frequently associated with adenocarcinoma histology.
• Higher proportion of patients with BM had positive PD-L1 expression (44.4%) compared to those without BM (29.8%).
• Median overall survival for NSCLC patients with BM has improved over time, approaching that of patients without BM.
• Advanced systemic therapies and focal radiotherapy contribute to improved intracranial control and survival.

Clinical Implications

Clinicians should consider that NSCLC patients with brain metastases may achieve survival outcomes comparable to those without BM when treated with modern CNS-active systemic therapies and stereotactic radiosurgery. Inclusion of patients with BM in clinical trials is increasingly justified to better evaluate treatment efficacy. Comprehensive genomic profiling and PD-L1 status remain important for guiding targeted and immunotherapy approaches in this population.

Conclusion

The prognosis of NSCLC patients with brain metastases has improved significantly in the era of advanced systemic and local treatments, challenging previous assumptions of uniformly poor outcomes. These findings support integrated treatment strategies and inclusion of BM patients in clinical research.

References

1. Evolving Survival Outcomes in Non-Small Cell Lung Cancer Patients with and without Brain Metastases Undergoing Advanced Treatment Approaches